Evidence map›Paper›PMID 39549073›Full record

SynthesisArchives of dermatological research2024

Efficacy and safety of Piclidenoson in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.

Muhammad Zain Ul Haq, Saad Ashraf, Ayesha Shaukat, Laveeza Fatima, Muhammad Shahmeer Ullah Shah, Muhammad Ahsan Ansari, Muhammad Nabeel Saddique, Gharira Batool, Javed Iqbal

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Archives of dermatological research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Muhammad Zain Ul HaqDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Saad AshrafDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Ayesha ShaukatDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Laveeza FatimaAllama Iqbal Medical College, Lahore, Pakistan.
Muhammad Shahmeer Ullah ShahDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Muhammad Ahsan AnsariDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Muhammad Nabeel SaddiqueKing Edward Medical University, Lahore, 54000, Pakistan.
Gharira BatoolLiaquat National Hospital and Medical College (LNHMC), Karachi, Pakistan.
Javed IqbalNursing Department, Communicable Disease Center, Hamad Medical Corporation, P.0 Box 3050, Doha, Qatar. jiqbal3@hamad.qa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriasis, an autoimmune inflammatory disease characterized by hyperproliferation of keratinocytes, affects 0.2-4.8% of the global population. The disease manifests primarily as plaque psoriasis, causing chronic physical and psychological burdens. Although numerous treatments exist, there is ongoing exploration for novel therapies due to concerns about the toxicity, efficacy, and costs of current options. An A3 adenosine receptor (A3AR) agonist called Piclidenoson has been shown to reduce inflammation and could be used to treat moderate to severe psoriasis. This meta-analysis evaluates the safety and efficacy of Piclidenoson in psoriasis treatment. This meta-analysis was conducted accordance with the PRISMA guidelines and has been registered on PROSPERO (CRD42024566459). A comprehensive search on Cochrane CENTRAL, PubMed/MEDLINE, and Google Scholar was conducted up to July 2024. Included studies were randomized controlled trials (RCTs) involving Piclidenoson. Efficacy outcomes included PASI 75 and PGA 0 or 1, while safety outcomes included adverse events. Pooled outcomes were presented as odds ratio (OR) with 95% confidence intervals (CI). Statistical analysis employed the Mantel-Haenszel random-effects model, and heterogeneity was assessed using the I

Indexed as

PsoriasisHumansRandomized Controlled Trials as TopicSeverity of Illness IndexTreatment OutcomeA3 adenosine receptorA3AR agonistMeta-analysisPiclidenosonPlaque psoriasisPsoriasis

Identifiers

PMID39549073
PMCPMC11568974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.